GITNUX MARKETDATA
Browse Our Category
Medical Conditions Disorders
Latest update:
Lobotomy Statistics
See how lobotomy outcomes swung from a 5 to 15 percent mortality ceiling to only 25 percent of discharges labeled fully recovered, even as schizophrenia “success” claims fell toward 20 percent long term and antipsychotics took over by the early 1970s. Then compare the grim tradeoffs of procedure and aftereffects with a concrete contrast such as 60 to 70 percent short term mania improvement and just 40 percent of intractable epileptics becoming seizure free, alongside the documented collapse in popularity as medications proved at least as effective for many patients.
Lymphedema Statistics
A 15%–20% risk can follow lymph node dissection plus radiation, yet nearly 44% report worsening after initial cancer treatment and 25% face a higher risk of cellulitis, so you will see how lymphedema can intensify even when care begins. This page connects prevalence, timing, and daily impact with evidence on what helps most, from complete decongestive therapy and compression to early detection and skin infection prevention.
Premature Birth Statistics
Preterm birth accounts for 35% of perinatal deaths worldwide, yet half of cases have no identified risk factor, turning prevention from a clear target into a puzzle. The page tracks what drives outcomes from infection and multiple gestations to medically indicated delivery, then follows the long tail through cerebral palsy, severe visual impairment, and major care costs, so you can see how “early” shapes health for years.
Black Women Breast Cancer Statistics
Black women with breast cancer still face a survival gap and care delays, even as 5 year relative survival sits at about 80% overall and TNBC is 77% for Black women versus 82% for White women. Learn how screening and follow up breakdowns drive late diagnosis and higher death rates, including 2.3 times higher odds of distant stage disease and a 41% higher breast cancer mortality rate compared with White women.
Alopecia Statistics
From lifetime risk to relapse rates, this page puts alopecia statistics in sharp focus, including about 2% of people worldwide and roughly 6.8 million in the United States living with alopecia areata. It also tracks how timing, hormones, and triggers change everything from a 39 to 86% relapse window after treatment to scarring forms that become irreversible, helping you separate common misunderstandings from what the evidence actually shows.
African American Heart Disease Statistics
From higher heart disease and stroke mortality, to the care gaps like 36% lower odds of getting a cardiac stress test and 25% lower odds of guideline statin therapy after MI, this page shows why disparities persist even when treatment exists. Updated with the latest numbers, including 15.3% of Black adults not seeing a doctor in the past year and community health worker and telehealth efforts making measurable dents, it ties the health outcomes directly to where prevention and care break down.
Rsv Statistics
RSV drives 2 to 3 million childhood hospitalizations worldwide each year and in US infants under 1 it lands at 1 in 38 during the first season. Get the practical context behind the risk and the tradeoffs, from bronchiolitis needing mechanical ventilation in 2 to 5 percent of hospitalized infants to testing performance and the payoff of prevention like nirsevimab and maternal vaccination.
Hyperthyroidism Statistics
Overt hyperthyroidism is about 1.3% globally and hits women 5 to 10 times more often than men, but the real twist is the biology behind the lab results. Graves’ TSH receptor antibodies drive 95% of cases, yet risk is also shaped by genetics, smoking which multiplies Graves’ orbitopathy by 8, pregnancy immune rebound, and even iodine overload, with TSH under 0.01 mU/L in 95% and thyroid ultrasound showing “thyroid inferno” in 95% of Graves.
Prediabetes Statistics
About 1 in 3 U.S. adults had prediabetes in 2015 and many never progress to diabetes, yet the cardiovascular and mortality risk stays higher, so the practical question is what actually works to interrupt the slide. From DPP style lifestyle programs and metformin’s longer payoff to real world results and updated A1C 5.7 to 6.4 screening targets, you will see which interventions move fasting glucose, reduce incidence, and help people stick with change.
Amniotic Fluid Embolism Statistics
Amniotic fluid embolism is rare, roughly 2 to 6 cases per 100,000 deliveries worldwide, yet it accounts for 5 to 10 percent of maternal deaths in developed countries and can be fatal in minutes. This page pulls together the most current incidence estimates and the timing, risk factors, and outcomes behind why a pregnancy complication that peaks after 37 weeks can still produce mortality rates and neurologic injury rates you will not expect from a condition that happens so seldom.
Acute Lymphoblastic Leukemia Statistics
Acute Lymphoblastic Leukemia is estimated to account for about 1,100 new U.S. cases in children and about 3,000 in adults in the latest 2024 Surveillance Research program estimates yet outcomes can swing dramatically based on MRD status and modern risk directed care. You will see how MRD based stratification can drop 5 year event free survival into the 40 to 60 percent range for MRD positive patients, where supportive care essentials like tumor lysis syndrome prophylaxis fit, and how targeted options and CAR T approvals such as tisagenlecleucel in 2017 and dasatinib for Ph plus ALL reshape the relapse landscape.
Turner Syndrome Statistics
From prenatal detection to the first endocrine labs, this page connects what is most often missed to what can be caught early, including NIPT sensitivity of 90 to 95% for monosomy X and echocardiogram screening at diagnosis that finds cardiac defects in 25 to 40% of Turner syndrome patients. You will also see why timing matters, with karyotyping requiring 20 to 30 cell analysis for classic cases and newborn chromosomal microarray able to pick up structural variants that karyotypes can miss.
Lung Cancer Treatment Statistics
Lung cancer remains a leading killer with 1,796,144 deaths worldwide in 2022, yet real-world survival and treatment outcomes hinge on fast, guideline backed decisions such as biomarker testing and biomarker matched therapy. See how U.S. lung cancer mortality runs at 33.2 per 100,000 and how targeted agents and immunotherapy are reshaping results, from 42% 1 year relative survival to driver mutation frequencies like EGFR, ALK, and KRAS, plus the practical costs, delays, and adherence gaps that influence whether patients actually get the right treatment on time.
Pregnancy Complications Statistics
Gestational diabetes affects 6 to 9% of pregnancies worldwide and insulin is needed in 15 to 20% of cases, yet simple screening timing can miss early disease in 10 to 20%. See how fasting and HbA1c thresholds, metformin versus insulin, and lifestyle control shift outcomes like stillbirth risk that can rise fourfold with uncontrolled hyperglycemia.
Neurofibromatosis Statistics
ADHD affects up to 30 to 50% of children with NF1 and cardiovascular complications such as hypertension track in reviews around 3 to 4% to 7%, yet NF1 affects roughly 1 in 2,500 to 3,000 births and only about 1.0% of U.S. adults self report a Neurofibromatosis diagnosis. From MEK inhibitor targeted therapy like selumetinib to MPNST survival that ranges 30% to 50% and plexiform neurofibroma malignant transformation near 8%, this page connects everyday risk to the decisions behind surveillance and treatment.
Autism Spectrum Disorder Statistics
Early screening tools can reach pooled sensitivity of 0.79 and specificity of 0.98 in community settings, yet many families still struggle to access timely, specialty care such as mental health services. See how evidence based interventions can improve communication, adaptive behavior, and irritability while costs and wait times in the US highlight the gap between what helps and what gets delivered.
Afib Statistics
Atrial fibrillation is surging with age, reaching about 9% in adults aged 80+ and affecting an estimated 60 million people worldwide by 2050, while also turning stroke risk about 5-fold higher and driving higher death rates around 20% to 30%. The page connects these stakes to real care gaps and outcomes, from a 2023 U.S. pattern of smoking among 36% of patients to anticoagulation choices and device detection timing that can change who gets protected.
Adhd Misdiagnosis Statistics
Nearly 1 in 3 adults with ADHD in the U.S. say they were diagnosed after childhood, yet multiple studies suggest many childhood referrals were originally facing something else, including alternative primary diagnoses found in about 12% to 20% after full assessment. If you are trying to understand how sleep problems, asthma, anxiety, and learning disorders can mimic ADHD long enough to delay the right treatment, this page puts the misdiagnosis signals and diagnostic switching risk front and center.
Von Willebrand Disease Statistics
Up to 75% of people with von Willebrand disease remain undiagnosed, even though FVIII can look normal in mild cases and mucocutaneous bleeding is reported in about 80% of patients, shaping a lifetime major bleeding incidence of around 29%. See how modern guidance ties together bleeding history with VWF activity and antigen thresholds, while the US hemophilia VWD treatment market is forecast at $9.6 billion in 2024 and the global market is projected to reach $2.9 billion by 2030.
Conversion Disorder Statistics
Conversion disorder is often mistaken for neurological disease, yet video EEG telemetry confirms 92% of PNES cases and EEG is normal in 98% of non epileptic seizures, making careful diagnosis the difference between the right treatment and a false label. This page brings together current accuracy benchmarks like 90% specificity and 75% sensitivity plus practical decision points such as ruling out MS and SLE first and why early intervention improves outcomes by 50%